BioTelemetry Inc. (NASDAQ:BEAT) was down 3.4% on Friday . The company traded as low as $20.57 and last traded at $20.58, with a volume of 129,983 shares traded. The stock had previously closed at $21.30.

A number of equities research analysts recently weighed in on BEAT shares. Zacks Investment Research upgraded BioTelemetry from a “hold” rating to a “buy” rating and set a $23.00 price objective on the stock in a research report on Thursday, August 4th. Benchmark Co. upped their price target on BioTelemetry from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, August 3rd.

The company’s 50 day moving average price is $18.94 and its 200-day moving average price is $14.83. The company has a market cap of $591.61 million and a PE ratio of 44.91.

BioTelemetry (NASDAQ:BEAT) last posted its earnings results on Tuesday, August 2nd. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.03. The company had revenue of $52.68 million for the quarter, compared to analysts’ expectations of $50.27 million. The company’s revenue was up 17.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.12 EPS. Equities research analysts expect that BioTelemetry Inc. will post $0.76 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in BioTelemetry stock. Wells Fargo & Company MN increased its stake in BioTelemetry Inc. (NASDAQ:BEAT) by 13.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 994,163 shares of the company’s stock after buying an additional 119,328 shares during the period. Wells Fargo & Company MN owned approximately 3.65% of BioTelemetry worth $11,612,000 as of its most recent SEC filing.

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.